Partners
Skopinpharm LLC
The modern, dynamically developing Russian pharmaceutical company, one of the leaders in the pharmaceutical industry of the Russian Federation in terms of growth rates.
Skopinpharm is a developer and manufacturer of medicines, one of the leading suppliers under the program of 14 high-cost nosologies in accordance with the Ministry of Health of the Russian Federation orders. Skopinpharm offers a range of medications under the regional preferential insurance program, and is also one of the main suppliers of the Circle of Good Foundation for helping children with serious and life-threatening illnesses. The company's turnover amounted to more than 44.1 billion rubles by 2024.
The company operates in the following key areas: manufacture of plasma-derived medicinal products, cytostatics, and medicinal products used for the treatment of various oncological diseases. As part of developing these business areas, the company has constructed new manufacturing and storage buildings, performs technology transfer of unique pharmaceutical manufacturing processes, and has built a plasma storage facility with a laboratory unit, which will ensure proper storage of plasma intended for fractionation (raw materials for the manufacture of human plasma-derived medicinal products).
At the same time, in partnership with health authorities, a modern system for the procurement of blood plasma is being created and a voluntary donation program is being developed.
Skopinpharm actively supports the training and advanced training of pharmaceutical industry specialists and is one of the founders of the Academy of Good Practices of the EAEU.
RZD-Medicine
RZD-Medicine: We are open to everyone
Today, RZD-Medicine is the largest private health care network in the country. It covers 71 regions and includes more than 360 outpatient and inpatient centres employing 53,000 people, 10,500 of whom are doctors. 2.2 million people are assigned to the network’s facilities, with the number of patients totalling 10 million in 2024.
RZD-Medicine is Russia’s largest industrial medicine network. There are 1,500 pre-trip medical check-up points across Russia: our specialists take responsibility not only for the health of Russian Railways employees but also for the lives of millions of Russians.
Railway medicine is an integral part of the national health care system. We provide high-quality and timely medical care to tens of thousands of residents of hard-to-reach and sparsely populated cities in Russia. There are 14 mobile medical units and a new medical train named “St Panteleimon” that runs through 8 regions of the Far East and Siberia.
Elena Zhidkova
Russian Railways Director for Medicine – Head of the Central Directorate of Health Care, a branch of Russian Railways
• Elena Zhidkova graduated from the Sechenov Moscow Medical Academy with a degree in Medicine and then completed her residency at the Department of Economics and Management there. In 2010, she took a course in marketing at the Moscow State University of Economics, Statistics and Informatics. Elena Zhidkova completed the MBA programme in Entrepreneurship and Company Management at the Russian Presidential Academy of National Economy and Public Administration. In 2019, she received a master’s degree from the Russian Presidential Academy of National Economy and Public Administration. In 2020, she completed the Executive Master in Public Management (EMPM) programme on developing the management talent pool.
• She is a candidate of medical sciences, author of numerous articles, publications and scientific and methodological works.
• Elena Zhidkova began her professional career in Moscow in 2011 at the Morozov Children’s City Clinical Hospital, where she headed consultative and diagnostic centres and outpatient and polyclinic services. In 2016, she headed the Central Directorate of Health Care, a branch of Russian Railways. In February 2025, she was appointed Russian Railways Director for Medicine – Head of the Central Directorate of Health Care, a branch of Russian Railways.
• Elena Zhidkova was awarded the medal of the Order “For Merit to the Fatherland, 2nd class” by a decree of the Russian President Vladimir Putin; а badge of honour “Excellent Health Care Worker” (2024). In December 2024, she was awarded the badge “For Selfless Devotion” of the Defenders of the Fatherland State Fund for Supporting Participants in the Special Military Operation
Swixx Healthcare LLC
Swixx BioPharma was founded to fully replace biopharma, OTC and medical device multinationals’ subsidiaries or business units in those countries, or therapeutic areas of CEE and beyond, that the multinational biopharma chooses not to enter, or to exit. With its expansion, Swixx BioPharma evolved into a professional and reliable partner with the highest standards in the areas where we operate.
At Swixx, we believe that everyone deserves access to the best medical solutions to live healthier and better lives. Although we are a pharmaceutical company without our own portfolio and research and development (R&D), we are committed to pursuing the standards and culture of a multinational pharmaceutical company.
We are highly experienced professionals, and our background is our strength. We joined forces and use our knowledge to constantly live up to our mission of providing access to the modern medicines of our partners.
For more information about Swixx, please visit: www.swixxbiopharma.com
Swixx Healthcare LLC
9, Zemlyanoj val
Moscow, 105064, Russian Federation
Phone +7 495 229 06 61
E-mail: russia.info@swixxbiopharma.com
Alisa Dzhangiryants
Deputy General Director, Market Access and Oncology, Swixx Healthcare LLC.
Alisa has over 20 years of experience in the pharmaceutical industry.
She worked at Roche for about 10 years in Marketing Department.
In 2012, Alisa joined Bristol-Myers Squibb as Project Manager for Immunology and Oncology in Market Access Department.
In 2014, she moved to the position of Regional Market Access Managers Head.
From 2017 to 2021, she held the position of Market Access and Pricing Department Director, during which time Alisa also had experience as Commercial Director and Acting General Director.
Since December 2021, she has been transferred to the position of Oncology Department Director.
In June 2022, Alisa joined Swixx Healthcare, as a Director of Oncology and Market Access Departments. Since January 2023, she has held the position of Deputy General Director.
Alisa graduated from the 1st Moscow State Medical University I.M. Sechenov, received a PhD in Pharmaceutical Sciences.
Association of Medical Specialists on Risk Modification (AMSRM)
The Association of Medical Specialists for Risk Modification was established in 2021 to attract the attention of the medical community and the general public to solving the problems of managing modifiable risk factors in order to prevent, effective primary and secondary prevention, treatment and rehabilitation of chronic non-communicable diseases, other syndromes, conditions and injuries leading to a loss of autonomy, a decrease in the quality and life expectancy of citizens. The focus of the Association's activities is the development and implementation at the federal level of programs for the comprehensive improvement of the quality of life of patients through the modification of risk factors and the creation of long-term motivation to change consumer behavior. The Association strive to organize a dialogue between all participants in the risk modification process - regulators, doctors, patients, social workers, business representatives.
Alexander Rozanov
Director of the Association of Medical Specialists for Risk Modification
Velpharm group
Velpharm Group is a pharmaceutical holding whose development strategy is to create a modern
business ecosystem for the full-cycle production of medicinal products.
Velpharm Group consists of several companies, the activity of each is aimed at implementing the overall
strategy of the Holding, including 3 production sites:
Velpharm - a pharmaceutical plant for the production of finished drugs in a full cycle:
production of finished drugs (Kurgan)
production of pharmaceutical substances (Kurgan, Dolgoprudny)
Velpharm-M - a new research and production complex for the development and production of
medicines, which owns its own R&D center (Moscow).
Today, Velpharm Group produces more than 120 socially significant drugs of various dosage forms and
different therapeutic categories, more than 70 drugs are at different stages of development and
registration.
Mission: working to preserve health and quality of people`s lives by creating modern, effective, safe and
affordable medicines.
Lyudmila Scherbakova
President, Bright Way Group of Companies; member of the Russian party, BRICS Women's Business Alliance
SHCHERBAKOVA Lyudmila Ivanovna The pharmaceutical holding company “Velpharm-Group” is a modern dynamically developing group which includes fullcycle pharmaceutical production companies. The development strategy of the group of companies is to create a business ecosystem for the production of pharmaceutical products, from pharmaceutical substances to finished drug products. The group of companies “Velpharm-Group” includes the following: LLC ”Velpharm“ (Kurgan) – a manufacturing pharmaceutical company. The plant produces more than 200 items of drugs, including drugs in the VED list. Production of pharmaceutical substances of iron complexes with various carbohydrates (sucrose, dextran, carboxymaltosate, etc.), bismuthate tripotassium dicitrate, propofol has been mastered. LLC “Velpharm” (Dolgoprudny city, Moscow Region) – production of pharmaceutical substances. For the first time in Russia, production of heparin and low molecular weight heparins on its basis – enoxaparin, nadroparin, dalteparin – has been mastered from domestic raw materials, which makes it possible to produce drugs on a full cycle from domestic raw materials.
President of the Velpharm Group of Companies Pharmaceutical industry Member of the Council of the Eurasian Women's Forum Member of the BRICS Women's Business Alliance Winner of the APEC Women Entrepreneurs International Competition (Stavropol region) 12.10.1955 LLC “Velpharm-M” (Moscow) was commissioned in January 2023. New research and production complex for the development and production of drugs. Production has started with a capacity of 5 billion tablets, 800 million capsules, 8 million sachets, 5 million pre-filled syringes per year. Own modern R&D center. Velpharm-M took 2nd place among the largest industrial facilities in Moscow built in 2023. Entered the Top 100 best public spaces in Russia in 2023. In 2024, the launch of the second phase of injectable drugs, lyophilisates, eye drops, soft gelatin capsules is planned. After full development, the company’s portfolio will include more than 400 types of drugs from various pharmacotherapeutic groups. LLC “Veltrade” (Moscow region) is a pharmaceutical company specializing in the production of dietary supplements and distribution of pharmaceutical substances and drugs.
JSC «GENERIUM»
Generium is a Russian innovative biotechnology company that combines a world-class research institute, a pre-clinical and clinical trial control center, and high-tech manufacturing.
The company has its own R&D park, which is capable to handle the full cycle of development of any medication, from molecule design to commercial production, including gene therapy and ATMPs. We are collaborating in science with biotechnological companies and institutes from all over the world.
GENERIUM is a leader in the orphan drug segment of Russian biotechnology. More than 30 medicinal products and diagnostic tools have been authorized over 15 years.
The production facilities of the enterprise are equipped with separate technological lines, and due to those we are able to produce a wide range of products. The quality of products is ensured by strict adherence to national and international standards of good manufacturing practice (GMP).
Dmitry Kudlay
Vice President for the Implementation of New Medical Technologies
Dmitry Kudlay is a Corresponding Member of the Russian Academy of Sciences, Doctor of Medical Sciences, and Vice President for the Implementation of New Medical Technologies at JSC "GENERIUM". He holds the positions of Deputy Dean at the Faculty of Fundamental Medicine at Moscow State University, Professor at the Department of Pharmacology at the Sechenov University, and Leading Researcher at the State Research Center "Institute of Immunology" of the FMBA of Russia.
He is a leading expert in the fields of fundamental and practical medical biotechnology, immunobiology, molecular diagnostics, and cell therapy. D.A. Kudlay's practical area of work involves the development, scaling-up of production, and implementation of therapeutic proteins and biomedical cell products for the diagnosis and treatment of severe socially significant diseases. He is the author of 592 scientific publications, including 18 monographs and practical guides, as well as 9 invention patents. The Hirsch index is 42
ООО «ВУ ЯНГ МЕДИКАЛ РУС»
Woo Young Medical Co., Ltd. (Korea) is a manufacturer of advanced professional medical devices, Accufuser® infusion pumps for single use and Accumate portable electronic pumps.
Woo Young Medical Co., Ltd. has 37% of the global infusion therapy products market.
Accufuser® infusion pumps are one-time-use devices that deliver medications with high precision.
Disposable sterile infusion pumps, promoting the reduction of the frequency of possible health problems and negative side effects, have found wide application in oncology, intensive care, surgery, postoperative anesthesia and therapy of chronic pain syndrome, antibiotic therapy, obstetrics, neonatology, narcology.
These high-accuracy devices permit treatment not only in hospital but also in ambulatory, home and even field settings.
The official exclusive representative of company products on the territory of the Russian Federation is WOO YOUNG MEDICAL RUS LLC.
Elena Mikheeva
General Director
Elena Mikheeva has been a head of the Russian representative office of the Korean manufacturer Woo Young Medical Co., Ltd since 2016. With her appointment, the company offers innovative medication delivery systems and elastomeric pumps, enabling patients to manage their pain level independently.
The company operates across the post-Soviet area, where WOO YOUNG MEDICAL RUS LLC holds a leading position in the Russian market, maintaining 37-40% market share thanks to Elena Mikheeva's exceptional leadership skills and the highly professional team that she has created.
Under Elena Mikheeva’s attentive guidance, the company continues to grow and implement cutting-edge technologies in the field of medical solutions, which confirms its status as a reliable partner in the healthcare sector.
Elena Mikheeva holds three higher education degrees: in Chemistry (the Kabardino-Balkar State University), Psychology (the Moscow State University), and Human Resource Management (the Higher School of Economics). Elena Mikheeva’ s knowledge and skills contribute to her successful management and effective interaction with the team.
Research Center of Neurology
Research Center of Neurology is the largest scientific and clinical neurological institution in Russia and one of the largest in Europe. It combines the experience of highly qualified clinical specialists and researchers in the field of basic neuroscience, which allows the results of experimental research to be effectively implemented in practice. The Center was founded in 1945. It has 5 clinical and research institutes, employing about 1000 doctors and scientists, among which there are 4 full members and 3 corresponding members of the Russian Academy of Sciences.
Annually, the Research Center of Neurology provides care for over 6 thousand patients in the hospital and conducts about 40 thousand outpatient consultations of patients in need of expert diagnostics and rehabilitation. The Center covers the entire spectrum of neurological diseases and performs neurosurgical interventions, including minimally invasive and endoscopic brain and spinal cord surgery, as well as functional neurosurgery using MRI-guided focused ultrasound.
The Research Center of Neurology is a leader in the field of clinical and experimental neurology, the results of which are published in highly rated international journals. The Center is regularly supported by multiple grants and megagrants. Together with leading Russian manufacturers, the Center participates in the development of high-tech products for neurosurgery and neurorehabilitation. It is also a major educational base for all levels of neurological training.
Mikhail Piradov
Director of the Research Center of Neurology
One of the recognised leaders of Russian neurology, widely known in our country and in the world.
Achievements
M. A. Piradov is the author of more than 900 scientific papers, including 15 monographs, 20 manuals and books, 26 patents for inventions. Hirsch index - 61 (RSCI), 30 (Web of Science). M. A. Piradov is a consultant and scientific supervisor of 6 doctoral and 26 candidate theses, the creator of his own scientific school in the field of neuroreanimatology. He made a significant contribution to solving the problems of neuroreanimatology and neurorehabilitation, including acute and chronic disorders of consciousness, brain death, severe strokes and polyneuropathies, myasthenic crises, early rehabilitation of patients in critical states, neuroplasticity. Under the leadership of M. A. Piradov, the Research Center of Neurology strengthened its leading position in the field of clinical neurology and fundamental neuroscience, gained new opportunities for development and significantly expanded the range of research areas, including through the creation of new areas of cooperation with leading research organisations and high-tech companies.
Education
2nd Pirogov Moscow State Medical Institute (1979). N.I. Pirogov (1979), clinical residency (1981) and Ph. D. fellowship in neurology the Research Institute of Neurology of the USSR Academy of Medical Sciences (1984), candidate of medical sciences (1984), doctor of medical sciences (1993), professor of neurology (1998), corresponding member of the Russian Academy of Medical Sciences (2011), corresponding member of the Russian Academy of Sciences (2014), full member of the Russian Academy of Sciences (2016), vice-president of the Russian Academy of Sciences (2022).
Experience
Head of the Research Centre of Neurology since 2014, having started his career at the Center as a clinical resident and neurologist. Also, in different years he was a part-time professor of the Department of Emergency Medicine with a course of emergency medical care at the Russian Medical Academy of Postgraduate Education, professor of the Department of Multidisciplinary Clinical Training at the Faculty of Fundamental Medicine of the Lomonosov Moscow State University, Head of the Department of Nervous Diseases with/from the A.I. Evdokimov Moscow State Medical and Dental University. Since 2022 - Vice-President of the Russian Academy of Sciences.
State awards
Two-time winner of the Russian Federation Government Prize in Science and Technology (2009, 2022). Awarded the Order of Friendship (2022), the Medal of the Order ‘For Merit to the Fatherland’ II degree (2016), the Medal of the Ministry of Education and Science of the Russian Federation ‘For Irreproachable Labour and Distinction’ (2023), the Commemorative Medal of S. S. Yudin ‘For Merit in Emergency Medicine’ (2023), the Badge of Honour ‘Excellence in Emergency Medicine’ (2023). Yudin ‘For Merits in Emergency Medicine’ (2023), Badge of Honour ‘Excellent Health Care Provider’ (2015), Certificates of Merit of the Russian Academy of Medical Sciences (2005, 2011), holder of the honorary title ‘Honorary Worker of Science and High Technology of the Russian Federation’ (2021).
Pharmasyntez Group
Pharmasyntez Group is one of the leading Russian biopharmaceutical companies operating in various segments of the healthcare industry, including research, development, production and distribution of socially important drugs, innovative medicine, and active pharmaceutical ingredients. Pharmasyntez Group's production facilities are represented by five high-tech plants across Russia: Ussuriysk, Irkutsk, Bratsk, Tyumen, and St. Petersburg. Annual output exceeds 100 million packs. The number of employees exceeds 4500.
The company develops and manufactures modern drugs for a wide range of medical fields, including oncology, hematology, endocrinology, immunology, cardiology, as well as for treatment of orphan, hormonal, infectious, autoimmune, cardiovascular, neuropsychiatric diseases, for therapy of diabetes, tuberculosis, hepatitis, HIV infection, COVID-19, chronic renal failure, drugs for maintaining the viability of patients in severe conditions - parenteral nutrition.
Pharmasyntez includes one of Russia's largest R&D centers for biotechnological drugs. Ongoing research and development will be a new generation of innovative methods for the fields of oncohematology, gynecology, virology, endocrinology.
The product portfolio consists of more than 300 drugs and more than 80 pharmaceutical substances. More than 80% of the drugs produced are included in the VED list.
The Company is the largest investor in Russian pharmaceutical industry. As of today, over 23 billion rubles have been invested in the development of production facilities and new developments.
NexTouch
NexTouch – is the leading Russian manufacturer of displays, interactive equipment, computing hardware and software solutions, including for educational and inclusive learning purposes.
NexTouch has been recognized as the top brand in the country. President of Russia Vladimir Putin has congratulated the company on its achievement, as well as on winning prestigious awards such as "Best Industrial Design in Russia" and "Brand of the Year in Russia".
The company operates a full production cycle, with a localization rate exceeding 80%, and manufactures over 45 different types of electronic devices, including displays, interactive panels, all-in-one computers, interactive tables for kids, professional screens, transparent displays, projection equipment, video conferencing systems, motherboards based on domestic processors and more.
These products are used in schools, universities, medical facilities, transportation, industry and other keys sectors of the economy.
Vladimir Krikushenko
Founder and CEO of JSC Nex-T and TM NexTouch
An author of the patents, including in the field of nanotechnology, software and special tools for people with disabilities, author of articles and his own methods of process management.
Vladimir is a member of the Board of the National Champions Association, member of the Board of Directors of the Association of children's goods industry, and an Ambassador of SEZ Technopolis Moscow, Member of the Expert Council of the Agency for Strategic Initiatives and Rosmolodezh.Business.
He has great experience in implementing innovative solutions in education, finance, labor productivity improvement, product innovation and research in nanotechnology and QLED displays based on quantum dots.
Under his management, NexTouch has gone through all stages of development, from a startup to a leading industry player with a market share exceeding 30%. The company continues to invest in R&D, electronic components development and manufacturing automation to maintain its position as a leader in the market.
NexTouch is building Russia's first facility for the mass production of LCD displays. Nex-T's bonds are traded on the Moscow stock exchange, and the company plans to go public through an IPO.
SmartLife
SmartLife is a health-tech company with its own production in Moscow. We produce vitamins of the future that will easily fit into your daily life today.
SmartLife is a leader in the production of liposomal vitamins in Russia. Using our own patented technology, we create vitamins in the most modern and bioavailable form - liposomal with an assimilation rate of up to 93%.
Encapsulation of nutrients in liposomes allows the active substance to get directly into the cells without loss or damage.
The company's mission is to produce exclusively honest products that really improve the quality of life and reduce the risk of developing various diseases.
"We don't do anything that we wouldn't give to our children!"